1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53.
2. Cancer incidence data, 2011; National Cancer Control Programme; Ministry of Health, Nutrition and Indigenous medicine Sri Lanka; Sri Lanka Cancer Registry, 13 publication at : https://www.nccp.health.gov.lk/images/PDF_PUBLICATIONS/Cancer_Incidence_Data_2011.pdf. Accessed 23 Dec 2021.
3. Ferraldeschi R, Newman WG. The impact of CYP2D6 genotyping on tamoxifen treatment. Pharmaceuticals. 2010;3(4):1122–38.
4. Saghafi F, Salehifar E, Janbabai G, Zaboli E, Hedayatizadeh-Omran A, Amjadi O, Moradi S. CYP2D6* 3 (A2549del),* 4 (G1846A),* 10 (C100T) and* 17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen. Biomedical reports. 2018;9(5):446–52.
5. Dean L. Tamoxifen therapy and CYP2D6 genotype. Medical Genetics Summaries. 2014.